2026 - Operationalizing ADC Clinical Trials: Best Practices for Success

As the oncology landscape evolves, antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in targeted cancer therapy. With 15 ADCs approved globally and more than 400 in development, the opportunity to advance patient outcomes has never been greater¹. Yet, success in ADC trials requires a deep understanding of the safety profile and the operational complexities that accompany these transformative therapies.
This webinar will explore strategies to optimize ADC clinical trial execution. Attendees will learn how to design protocols geared towards dose optimization by applying Project Optimus principles, navigate global site selection and implement appropriate site training using ADC-specific patient education and toxicity management tools. This webinar will also highlight how biomarker-driven enrollment, streamlined screening, toxicity management and reduced procedural burden can enhance recruitment and retention while improving overall patient experience.
Register for this webinar to learn how ADC clinical trials can be optimized through operational excellence and thoughtful study design.
Sources:
Wang, R., Hu, B., Pan, Z. et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18, 51 (2025). https://doi.org/10.1186/s13045-025-01704-3
Keywords: ADCs, Antibody-Drug Conjugate, Cancer, Clinical Research, Clinical Trial Design, Clinical Trials, CRO, Drug Development, Oncology, Oncology Clinical Trials, Oncology Drug Development, Therapeutic Areas